Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16640714 | 0.84 | LPAR1 (0.48) | MGLL | |
| SCHEMBL1715067 | 0.84 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2TDP1TP53CYP3A4 | |
| Water SCHEMBL28201965 | 0.82 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2TDP1TP53CYP3A4 | |
| SCHEMBL28197584 | 0.82 | CA2 (0.45) | ALDH1A1SMN1; SMN2TLR4MGLL | |
| SCHEMBL1441621 | 0.81 | LPAR1 (0.51) | MGLL | |
| Water SCHEMBL28201966 | 0.81 | CA2 (0.44) | ALDH1A1SMN1; SMN2TLR4MGLL | |
| SCHEMBL28096991 | 0.80 | ALDH1A1 (0.45) | ALDH1A1TP53CYP3A4MGLL | |
| SCHEMBL14256247 | 0.79 | ALDH1A1 (0.50) | ALDH1A1TP53CYP3A4MGLL | |
| SCHEMBL29049547 | 0.78 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2TDP1TLR4 | |
| SCHEMBL11969676 | 0.77 | LMNA (0.53) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119510-A1 | GLYCIDYL ESTERS OF ALPHA, ALPHA BRANCHED ACIDS COMPOSITIONS | HEXION INC. (US) | 2019-04-25 | — | — | US | disclosed |
| EP-2661430-B1 | GLYCIDYL ESTERS OF ALPHA, ALPHA BRANCHED ACIDS COMPOSITIONS | HEXION RES BELGIUM SA (BE) | 2018-11-14 | — | — | EP | disclosed |
| US-20140005300-A1 | GLYCIDYL ESTERS OF ALPHA, ALPHA BRANCHED ACIDS COMPOSITIONS | MOMENTIVE SPECIALITY CHEMICALS INC. (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2661430-A1 | GLYCIDYL ESTERS OF ALPHA, ALPHA BRANCHED ACIDS COMPOSITIONS | Momentive Specialty Chemicals Research Belgium S.A. (BE) | 2013-11-13 | — | — | EP | disclosed |
| WO-2012084265-A1 | GLYCIDYL ESTERS OF ALPHA, ALPHA BRANCHED ACIDS COMPOSITIONS | MOMENTIVE SPECIALTY CHEMICALS RESEARCH S.A. (BE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119510-A1 | GLYCIDYL ESTERS OF ALPHA, ALPHA BRANCHED ACIDS COMPOSITIONS | GNE, B3GAT3, GALE | ALDH1A1 991/4885SMN1; SMN2 483/4885TDP1 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.